Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in patients with hypercholesterolemia and hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Esperion Therapeutics; Esperion Therapeutics, Inc.
• Collaborator: Medpace, Inc.
• Treatments: 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid

Criteria

Inclusion Criteria:

• Mean 24-hour ambulatory SBP greater than or equal to 130 mmHg

• or- Mean 24-hour ambulatory DBP greater than or equal to 80 mmHg

• Fasting LDL-C between 100 and 220 mg/dL

• Fasting triglycerides less than 400 mg/dL

• Body mass index (BMI) between 18 and 45 kg/m2

Exclusion Criteria:

• Known or suspected secondary hypertension or history of malignant hypertension

• Taking more than two anti-hypertension medications at the first visit

• History or current clinically significant cardiovascular disease

• History or current type 1 diabetes or type 2 diabetes